Impact of neoadjuvant chemotherapy with FOLFOX/FOLFIRI on disease-free and overall survival of patients with colorectal metastases

Journal of Gastrointestinal Surgery

Volumn 13, Issue 11, 2009, Pages 2003-2010

  Boostrom, Sarah Y ^a   Nagorney, David M ^a   Donohue, John H ^a   Harmsen, Scott ^a   Thomsen, Kristine ^a   Que, Florencia ^a   Kendrick, Michael ^a   Reid Lombardo, Kaye M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Neoadjuvant therapy. FOLFOX. Hepatectomy. Colorectal cancer metastases. Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLUOROURACIL; FOLFOX PROTOCOL; FOLINIC ACID; IFL PROTOCOL; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RETROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 77952993629     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-009-1007-3     Document Type: Article

References (24)

1. SEER Cancer Statistics Review, 1975-2003, LAG Ries, et al.,Editors. 2006, National Cancer Institute: Bethesda, MD, http:// seer.cancer.gov/csr/1975_2003/, based on November 2005 SEER data submission, posted to the SEER web site. p. 1-25.
2. Lee JJ, Chu E. An update on treatment advances for the first-line therapy of metastatic colorectal cancer. Cancer J 2007;13:276-281
3. Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giuliante F, D'Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007;97:1035-1039
4. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318. discussion 318-321.
5. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996;224:509-520. discussion 520-522.
6. Fortner JG, Silva JS, Cox EB, Golbey RB, Gallowitz H, Maclean BJ. Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer. II. Treatment by intra-hepatic chemotherapy. Ann Surg 1984;199:317-324.
7. Adson MA, van Heerden JA, Adson MH, Wagner JS, Ilstrup DM. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984;119:647-651.
8. Scheele J, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K. Resection of colorectal liver metastases. What prognostic factors determine patient selection? Chirurg 2001;72:547-560
9. Pawlik TM, Choti MA. Surgical therapy for colorectal metastases to the liver. J Gastrointest Surg 2007;11:1057-1077
10. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997;15:938-946.
11. Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002;235:759-766.
12. Lubezky N, Geva R, Shmueli E, Nakache R, Klausner JM, Figer A, Ben-Haim M. Is there a survival benefit to neoadjuvant versus adjuvant chemotherapy, combined with surgery for resectable colorectal liver metastases? World J Surg 2009;33:1028-1034
13. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghemard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004;240:644-657. discussion 657-658.
14. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005;23:9243-9249.
15. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109-115. discussion 116-117
16. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, Group EG-ITC, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft O, Australasian Gastro-Intestinal Trials G, Federation Francophone de Cancerologie D. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.[see comment]. Lancet 2008;371:1007-1016.
17. Hamady ZZ, Malik HZ, Finch R, Adair R, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP. Hepatic resection for colorectal metastasis: impact of tumour size. Ann Surg Oncol 2006;13:1493-1499.
18. Tanaka K, Adam R, Shimada H, Azoulay D, Levi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003;90:963-969
19. Sugawara Y, Yamamoto J, Yamasaki S, Shimada K, Kosuge T, Makuuchi M. Estimating the prognosis of hepatic resection in patients with metastatic liver tumors from colorectal cancer with special concern for the timing of hepatectomy. Surgery 2001;129:408-413.
20. Jatzko G, Wette V, Muller M, Lisborg P, Klimpfinger M, Denk H. Simultaneous resection of colorectal carcinoma and synchronous liver metastases in a district hospital. Int J Colorectal Dis 1991;6:111-114
21. Lyass S, Zamir G, Matot I, Goitein D, Eid A, Jurim O. Combined colon and hepatic resection for synchronous colorectal liver metastases. J Surg Oncol 2001;78:17-21.
22. Doko M, Zovak M, Ledinsky M, Mijic A, Peric M, Kopljar M, Culinovic R, Rode B, Doko B. Safety of simultaneous resections of colorectal cancer and liver metastases. Coll Antropol 2000;24:381-390.
23. Vauthey J-N, Pawlik TM, Ribero D, Wu T-T, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.[see comment]. J Clin Oncol 2006;24:2065-2072.
24. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluoro-uracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006;24:4983-4990.